The Management Board of Selvita S.A. with its registered office in Krakow (“Selvita”) hereby announces that the company affiliated with Selvita – Fidelta d.o.o. (“Fidelta”) with its registered office in Zagreb, Croatia has concluded on 22th July 2021 a purchase order under a framework agreement executed on 1st October 2018, between Fidelta and a biotechnological company with its registered office in Europe (“Client”) with a total value of EUR 4,011,055 (PLN 18,359,802.05 converted at the rate EUR 1 = PLN 4.5773). The objective of the purchase order is Hit to Lead optimization of chemical series for the treatment of idiopathic pulmonary fibrosis (IPF) over the following 18 months (until 31 December 2022). Fidelta, in its laboratories in Zagreb, will provide services in the area of medicinal chemistry; computer aided drug design (CADD); in vitro and in vivo Pharmacology; ADME,DMPK and Phys-Chem profiling and analytical support.

The total value of the services that will be provided by Fidelta to the Client in 2021 will amount to EUR 4,600,831 (PLN 21,059,383.74) converted at the above-mentioned exchange rate).

Taking into account value of the purchase order, its scope, as well the fact that the Client has expanded cooperation with Fidelta, the Company’s Management Board considers the order to be significant for the implementation of Selvita Group’s long-term plans aiming at building a strong position on the international preclinical CRO (Clinical Research Organization) market.

Legal basis: Art. 17 par. 1 of MAR

Representatives of the Company:
•Bogusław Sieczkowski – President of the Management Board
•Dariusz Kurdas – Member of the Management Board